Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · New England Journal of Medicine · 4,519 citations
https://doi.org/10.1056/nejmoa1207506
P
Paul N. Mainwaring
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
196
Papers
26.4K
Citations
49
h-index
89
i10-index
Paul N. Mainwaring is an academic researcher from The University of Queensland. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Treatment and Pharmacology & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 49, co-authored 167 publications.
ORCID: 0000-0003-4462-5988Papers by this author
worksAbiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · New England Journal of Medicine · 4,346 citations
https://doi.org/10.1056/nejmoa1014618
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
2014 · New England Journal of Medicine · 3,004 citations
https://doi.org/10.1056/nejmoa1405095
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
2018 · New England Journal of Medicine · 1,305 citations
https://doi.org/10.1056/nejmoa1715546
A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy
2021 · Nature Communications · 138 citations
https://doi.org/10.1038/s41467-021-21431-w
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
2010 · Annals of Oncology · 103 citations
https://doi.org/10.1093/annonc/mdq430
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat